首页> 外文期刊>Sarcoma >Bisphosphonate treatment of benign multifocal and unifocal osteolytic tumours of bone
【24h】

Bisphosphonate treatment of benign multifocal and unifocal osteolytic tumours of bone

机译:双膦酸盐治疗良性多灶性和单灶性骨溶解性肿瘤

获取原文
获取原文并翻译 | 示例
       

摘要

Growth of benign tumours and tumour-like lesions of bone results in osteolysis which may cause pathological fracture. Bisphosphonates are anti-osteolytic agents which have proved effective in the treatment of number of osteolytic conditions. In this study we report the results of treatment with the aminobisphosphonate, pamidronate, of three benign osteolytic tumours of bone, two cases of fibrous dysplasia and one of Langerhans cell histiocytosis. In all three cases there was clinical and radiological improvement following treatment. Radiologically, bone lesions did not exhibit progressive enlargement. Two cases of fibrous dysplasia also showed features suggestive of increased bone formation. These findings indicate that bisphosphonates are likely to be useful in controlling the osteolysis of benign tumours/tumour-like lesions of bone, particularly in those cases where surgical, intervention is not possible or multifocal lesions are present.
机译:良性肿瘤的生长和骨骼的肿瘤样病变会导致骨溶解,从而可能导致病理性骨折。双膦酸盐是抗溶骨剂,已被证明可有效治疗多种溶骨病。在这项研究中,我们报告了使用氨基双膦酸盐,帕米膦酸盐治疗三种骨性良性溶骨性肿瘤,两例纤维性异型增生和一例朗格汉斯细胞组织细胞增生症的治疗结果。在所有三种情况下,治疗后临床和放射学均有改善。在放射学上,骨病变未表现出进行性扩大。 2例纤维异常增生也表现出提示骨形成增加的特征。这些发现表明,双膦酸盐可能在控制良性肿瘤/骨肿瘤样病变的骨溶解中有用,特别是在不能进行手术,干预或存在多灶性病变的情况下。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号